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ABSTRACT
Introduction: DPP-4 inhibitors (DPP4i) and
sulfonylureas are popular second-line therapies
for type 2 diabetes (T2D), but there is a paucity
of real-world studies comparing their effective-
ness in routine clinical practice.
Methods: This was a multicenter retrospective
study on diabetes outpatient clinics comparing
the effectiveness of DPP4i versus gliclazide
extended release. The primary endpoint was
change from baseline in HbA1c. Secondary
endpoints were changes in fasting plasma glu-
cose, body weight, and systolic blood pressure.
Automated software extracted data from the
same clinical electronic chart system at all
centers. Propensity score matching (PSM) was
used to generate comparable cohorts to perform
outcome analysis.
Results: We included data on 2410 patients
starting DPP4i and 1590 patients starting gli-
clazide (mainly 30–60 mg/day). At baseline, the
two groups differed in disease duration, body
weight, blood pressure, HbA1c, fasting glucose,
HDL cholesterol, triglycerides, liver enzymes,
eGFR, prevalence of microangiopathy, and use
of metformin. Among DPP4i molecules, no
difference in glycemic effectiveness was detec-
ted. In matched cohorts (n = 1316/group),
patients starting DPP4i, as compared with
patients starting gliclazide, experienced greater
reductions in HbA1c (- 0.6% versus - 0.4%;
p\0.001), fasting glucose (- 14.1 mg/dl versus
- 8.8 mg/dl; p = 0.007), and body weight
(- 0.4 kg versus - 0.1 kg; p = 0.006) after an
average 6 months follow-up. DPP4i improved
glucose control more than gliclazide, especially
in patients who had failed with other glucose-
lowering medications or were on basal insulin.
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INTRODUCTION
The rapid evolution of diabetes pharmacother-
apy and the availability of many glucose-low-
ering medication (GLM) classes for the
treatment of type 2 diabetes (T2D) have made
the choice of second-line agents after met-
formin an difficult task [1]. Ideally, patient
characteristics should be matched with drug
modes of action, favorable effects, and side
effects. However, this is not always possible
because of restrictions in drug indications,
availability, reimbursement, and contraindica-
tions. Furthermore, translating results of phase
III randomized controlled trials (RCTs) to clini-
cal practice may be problematic owing to the
many differences between trial and routine care
settings [2].
In many countries, the two most popular
second-line GLMs for the treatment of T2D are
sulfonylureas (SUs) and dipeptidyl peptidase 4
inhibitors (DPP4i). RCTs that directly compared
drugs of these classes showed that SUs tend to
be more effective than DPP4i in reducing HbA1c
over the short term, but that such differences
are mostly lost in the long run [3]. Rather,
compared with SU, DPP4i have been associated
with a markedly lower risk of hypoglycemia and
a mild benefit in the control of body weight [4].
In addition, while three large placebo-con-
trolled RCTs support the cardiovascular safety
of DPP4i [5–7], SUs have been linked with an
increased risk of cardiovascular events and
mortality, although such data derive mainly
from observational studies [8, 9]. Gliclazide is
often considered the preferred SU, because it
has been associated with greater than 50% less
hypoglycemia risk [10] and a safer cardiovascu-
lar risk profile [11] compared with other SUs.
Furthermore, gliclazide is by far the mostly
widely used SU in Italy [12] and its relative
cardiovascular safety has been recently con-
firmed in the Italian TOSCA.IT study [13].
Despite SUs and DPP4i being very popular
GLMs, there is a striking paucity of real-world
studies comparing the effectiveness of these
drugs in routine clinical practice. This is par-
ticularly important since SUs are still perceived
as highly effective drugs for the control of
hyperglycemia and their low cost makes them
particularly attractive for healthcare systems
with limited resources. Thus, comparative real-
world studies on these drugs may complement
information from RCTs and inform on thera-
peutic appropriateness.
The DARWIN-T2D was a multicenter retro-
spective study conducted on electronic medical
records containing clinical data, performed at
46 diabetes specialist outpatient clinics in Italy
[14]. We herein report results of a subanalysis
comparing the effectiveness of DPP4i versus
gliclazide on glycemic and extra-glycemic
endpoints.
METHODS
Data Source
The main objective of the DARWIN-T2D study
was to describe the clinical characteristics and
the changes from baseline in glycemic and
extra-glycemic effectiveness parameters in
patients newly treated with the SGLT2 inhibitor
dapagliflozin, a DPP4i, gliclazide, or a GLP-1
receptor agonist [14]. The study was conducted
at 46 Italian diabetes outpatient clinics. The
detailed study protocol and the primary results
have been previously published [14]. Results of
the study indicated a significant channelling of
different patients towards different GLMs, and
an overall low common support between
patients receiving dapagliflozin and other GLMs
[12]. The largest common support of propensity
scores was detected for patients starting DPP4i
and patients starting gliclazide, thereby pro-
viding a rationale for comparing effectiveness of
such drugs.
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Patients were retrospectively included if they
were aged 18–80 years, had a diagnosis of T2D
for at least 1 year, and were newly prescribed
with a full-dose DPP4i (per protocol, linagliptin
was excluded [14]), or with gliclazide extended
release at a daily dose of 30 mg or higher.
Exclusion criteria were a diagnosis of type 1
diabetes and age less than 18 or greater than
80 years.
Dedicated software automatically extracted
all relevant clinical data (demographics,
anthropometrics, blood pressure, HbA1c, fast-
ing plasma glucose, lipid values, liver enzymes,
renal function, history of complications, and
medications) at baseline and at the first avail-
able follow-up visit, 3–12 months after baseline.
LDL cholesterol levels were calculated using
Friedewald’s equation [15], whereas eGFR (esti-
mated glomerular filtration rate) was computed
using the CKD-EPI equation [16]. Microan-
giopathy was defined as the presence of an
albumin excretion rate greater than 30 mg/24 h
or mg/g of creatinine, an eGFR less than 60 ml/
min/1.73 m2, diabetic neuropathy (either
somatic or autonomic), diabetic retinopathy
(any grade), or maculopathy. Macroangiopathy
was defined as the presence of a history of
myocardial infarction or stroke/transient
ischemic attack, peripheral arterial disease, sur-
gical or endovascular revascularization (any
site), or a diagnosis of asymptomatic
atherosclerosis. We retrieved information on all
concomitant medications and on the entire
history of GLM use to define whether patients
were being prescribed DPP4i or gliclazide as
second-line agents after metformin (i.e., had
been treated only with metformin) or after
failure of at least another GLM different from
metformin.
The primary effectiveness endpoint was the
change from baseline in HbA1c. Secondary
endpoints were changes from baseline in fasting
plasma glucose, body weight, and systolic blood
pressure. We excluded patients without a fol-
low-up examination, those with missing data
for the primary outcome at baseline or follow-
up, and those initiating DPP4i and gliclazide at
the same visit (because the effect could not be
attributed to one or the other). All data were
extracted automatically from the same
electronic chart system (MyStar Connect,
Me.Te.Da.).
Multiple Imputation and Propensity Score
Matching
For a comparative analysis of effectiveness, we
used propensity score matching (PSM), one of
the most popular methods to estimate treat-
ment effects in observational studies [17]. In a
trade-off between unconfoundedness and pre-
cision, the following baseline covariates were
chosen for PSM as they are expected to affect
outcomes and therapy assignment: age, gender,
diabetes duration, BMI, body weight, systolic
and diastolic blood pressure, FPG, Hb1Ac, total
cholesterol, HDL cholesterol, triglycerides,
aspartate aminotransferase, alanine amino-
transferase, eGFR, insulin as associated therapy,
metformin as associated therapy, use of DPP4i
or gliclazide as second-line therapy, microan-
giopathy and macroangiopathy. Presence of
missing data was handled with multiple impu-
tation (MI), as previously described [18]. Out-
comes and selected variables were used as
predictors in MI models [19]. A PS model was
fitted on each imputed data set and the final
individual PS value was computed as the aver-
age of all the subject PS values obtained in each
imputed data set. Then, PS values were used to
create a matched set of individuals from the
original non-imputed data set. Matching was
performed with 1:1 ratio, i.e., each subject
treated with DPP4i was matched with only one
subject treated with gliclazide, using a genetic
algorithm, without replacement. Covariate bal-
ance after matching was evaluated using stan-
dardized mean difference across group of
treatment and standardized mean differences of
the square of continuous variables. Balance was
achieved if standardized difference was less than
0.1. Outcome analysis was conducted on a
matched set of individuals obtained after PSM.
Effect of treatment on outcomes was evaluated
with adjusted linear regression models, with
confidence intervals computed using a robust
sandwich estimator. More details on MI and
PSM can be found in the Online Supplementary
Material.
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Statistical Analysis
Except where otherwise specified, data are pre-
sented as mean ± standard deviation or as per-
centage, as appropriate. Comparisons between
the two groups of patients (e.g., those receiving
DPP4i and those receiving gliclazide) were per-
formed using the 2-tail unpaired Student t test for
continuous variables, or the chi-square test for
categorical variables. Differences in clinical char-
acteristics between matched cohorts were better
analyzed using standardized bias than using p
values, as previously suggested [13]. Comparisons
in continuous variables among more than two
groups was performed using ANOVA with Bon-
ferroni correction. Evaluation of within-group
changes in outcome variables was performed
using the 2-tail paired Student’s t test. Changes
from baseline in outcome variables were calcu-
lated for each group as data collected at follow-up
minus data collected at baseline, and compared
using the 2-tail unpaired Student t test. To analyze
the time trend of HbA1c reduction in the two
groups, we divided the 9-month observation
window (3–12 months after baseline) into five
equal periods and assigned each patient to the
relevant follow-up duration. Statistical signifi-
cance was accepted at p\0.05.
Compliance with Ethics Guidelines
The study was approved by the ethical committee
of each participating center. All procedures per-
formed in studies involving human participants
were in accordance with the ethical standards of
the institutional and/or national research com-
mittee and with the 1964 Declaration of Helsinki
and its later amendments or comparable ethical
standards. Since the study was performed retro-
spectively on an anonymized database, no patient
consent was required.
RESULTS
Study Population
The studyflowchart is shown inFig. 1. Between15
March 2015 and 31 December 2016, we collected
baseline data on 6594 T2D patients who initiated
therapy with a DPP4i (53.2% sitagliptin, 22.9%
alogliptin, 20.6% vildagliptin, 3.3% saxagliptin)
and 5960 patients who initiated therapy with
gliclazide. Of these, 2999 patients treated with
DPP4i (45.5%) and 2111 patients treated with
gliclazide (35.4%), had a follow-up visit available
between 3 and 12 months after baseline; 589
patients treated with DPP4i and 521 treated with
gliclazide were excluded for missing data for the
primary outcome or because they initiated both
drugs at the same time (n = 151). Data on the
remaining 2410 DPP4i users and 1590 gliclazide
users are shown in Table 1. Patients newly treated
with gliclazide versus those newly treated with
DPP4i had longer disease duration, higher body
weight, BMI, systolic blood pressure, HbA1c,
fasting plasma glucose, triglycerides, and liver
enzymes, and lower HDL cholesterol and eGFR.
Patients starting gliclazide also had a higher
prevalence of microangiopathy and less frequent
use of metformin than patients starting a DPP4i.
Within-Group Effectiveness Analysis
After a median follow-up of 6.1 months (IQR
5.5–6.7), in patients who received a DPP4i,
HbA1c declined by 0.6%, fasting plasma glucose
declined by 11.4 mg/dl, body weight declined
by 0.5 kg, with no significant change in systolic
blood pressure (Table S1). Among DPP4i, no
significant difference was observed in the
change from baseline in HbA1c, fasting plasma
glucose, and systolic blood pressure, while
reductions in body weight were larger for sita-
gliptin and alogliptin than for vildagliptin
(Fig. S1).
After a median follow-up of 6.2 months (IQR
4.8–7.1), in patients who received gliclazide,
HbA1c declined by 0.6% and fasting plasma
glucose declined by 14.5 mg/dl, while no sig-
nificant change was observed for body weight
and blood pressure (Table S1).
Comparison of Propensity Score Matched
Groups
PSM was performed on a predefined set of
variables, which were considered to be clinically
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relevant for the outcome and therapy assign-
ment. After MI, PSM identified 1316 patients in
each group, who were well balanced for all
clinical variables except concomitant use of
basal insulin, which was significantly more
common in patients starting a DPP4i (17.4%)
versus those starting gliclazide (13.2%) (Fig. S2).
In matched cohorts (Fig. 2), the change from
baseline in HbA1c was significantly higher in
patients starting DPP4i than in those starting
gliclazide (- 0.6 ± 1.1% versus - 0.4 ± 1.2%;
p\0.001). The same was true for fasting plasma
glucose (- 14.1 ± 43.5 mg/dl versus
- 8.8 ± 46.2 mg/dl; p = 0.007) and body weight
(- 0.4 ± 3.3 kg versus - 0.1 ± 2.9 kg;
p = 0.006), while the between-group difference
in the change from baseline in systolic blood
pressure did not reach statistical significance
(- 1.5 ± 19.8 mmHg versus 0.3 ± 18.9 mmHg;
p = 0.056).
The use of concomitant GLM did not sig-
nificantly change at follow-up compared to
baseline in either group (Fig. S3).
By dividing patients according to distance
between baseline and follow-up, we simulated a
time course of HbA1c reduction: while patients
who received gliclazide show a progressively
lower glycemic effect with longer follow-up,
such loss of effectiveness was not observed with
DPP4i (Fig. S4).
After we adjusted for concomitant insulin
use, patients starting DPP4i still showed greater
reductions in HbA1c and body weight than
those starting gliclazide (Fig. S5). In models
fully adjusted for basal insulin, each variable at
baseline (either linearly or non-linearly mod-
elled), and interaction terms, DPP4i proved
superior to gliclazide in reducing HbA1c, FPG,
body weight, and systolic blood pressure
(Table S2).
Figure 3 shows the changes in HbA1c, FPG,
body weight, and systolic blood pressure in the
matched cohorts of patients with or without
concomitant insulin therapy and in those ini-
tiating DPP4i or gliclazide as second-line ther-
apy after metformin or as a more advanced line
of therapy. Patients starting DPP4i experienced
a stronger HbA1c reduction than patients
starting gliclazide, irrespective of background
insulin therapy, but the between-group differ-
ence was significantly larger in insulin-treated
patients. Only in patients who were on insulin
therapy, DPP4i reduced fasting plasma glucose
more than gliclazide. Vice versa, only in
Fig. 1 Study flowchart. DPP4i dipeptidyl peptidase 4 inhibitors, PSM propensity score matching
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patients who were not on insulin, DPP4i
reduced body weight more than gliclazide. An
interaction between type of new prescription
(DPP4i vs gliclazide) and background insulin
therapy in determining the change from base-
line in HbA1c, fasting plasma glucose, and body
weight was confirmed upon a multivariable
analysis (Table S2).
In patients who started DPP4i or gliclazide as
second-line therapy after metformin, no signif-
icant difference was noted in the changes from
baseline in HbA1c, fasting plasma glucose, body
weight, and systolic blood pressure. Rather, in
patients starting DPP4i or gliclazide as third or
more advanced line of therapy, reductions in
HbA1c, fasting plasma glucose, body weight,
and systolic blood pressure were greater with
DPP4i than with gliclazide.
DISCUSSION
This large retrospective real-world study
demonstrates that, in routine diabetes outpa-
tient clinical practice, addition of a DPP4i to the
ongoing therapy improved glucose control
more than addition of gliclazide. This was par-
ticularly true in patients who were receiving
DPP4i or gliclazide after having failed with at
least another GLM different from metformin
and in those who were on basal insulin.
These findings contrast with results of phase
III RCTs comparing DPP4i with SUs, which
show that DPP4i are less effective than SUs in
reducing HbA1c in the short term and are non-
inferior to SUs in the long term. A few reasons
can explain these results. First, the broader
population of patients included in this real-
world study differs from that of phase III RCTs,
especially in terms of age, history of GLM use,
complication burden, and overall heterogene-
ity. Second, phase III RCT protocols require that
SUs are uptitrated to the maximal tolerated
dose, which is rarely reached in clinical practice,
especially in aged patients with chronic com-
plications. While we do not have full informa-
tion about dose titration in the DARWIN-T2D
study, gliclazide extended release is usually
prescribed at the initial daily dose of 30–60 mg
Fig. 2 Comparative effectiveness in matched cohorts.
Baseline, follow-up data, and the change from baseline
are shown for the primary outcome (HbA1c, a) and for
secondary outcome measures: fasting plasma glucose (FPG,
b), body weight (c), and systolic blood pressure (SBP, d).
*p\ 0.05 for the indicated comparisons. Bars indicate
standard error
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and not uptitrated until the following visit.
Indeed, cross-sectional data from pilot study
centers indicate that the average daily gliclazide
dose was 49 mg. Thus, it is possible that DPP4i
allowed a better improvement in glucose con-
trol because gliclazide was being used at a rela-
tively low dose. As doses of gliclazide, but not of
DPP4i, can be uptitrated over time, it is possible
that a longer observation would have produced
different results. It is nonetheless remarkable
that, at doses used in routine clinical practice,
initiation of DPP4i provides a better glycemic
control than initiation of gliclazide at the first
follow-up visit after about 6 months.
Of note, even in the larger cohort of patients
before PSM, the various DPP4i provided similar
improvements in HbA1c and fasting glucose
and differed only in the change in body weight.
These data indicate that, from a practical per-
spective, DPP4i do not differ in their glycemic
effectiveness.
Interestingly, by dividing study patients
according to the time elapsed from baseline to
follow-up visits, we simulated a time course of
HbA1c change. Although this approach cannot
be equated to a longitudinal observation in the
same patients, it suggests that gliclazide lost
effectiveness over time more than DPP4i, a
trend present also in long-term phase III RCTs.
Remarkably, the history of previous glucose-
lowering therapy had an impact on the com-
parative effectiveness. In patients who were
prescribed DPP4i or gliclazide as second-line
drugs after metformin, i.e., who had received no
GLM other than metformin, the improvement
in glucose control was similar with the two
treatment regimens. This is more in line with
results of phase III RCTs, wherein patients with
T2D, usually of short duration, uncontrolled on
metformin monotherapy, were randomized to
DPP4i or SUs. However, in patients in whom at
least another GLM had failed, DPP4i was supe-
rior to gliclazide in improving HbA1c, FPG,
body weight, and blood pressure. Furthermore,
DPP4i retained a significant glucose-lowering
effect when added to combination of basal
Fig. 3 Comparison of effectiveness according to concomi-
tant and previous therapy. The changes in HbA1c (a),
fasting plasma glucose (FPG, b), body weight (c), and
systolic blood pressure (SBP, d) are shown for the entire
cohorts of matched patients (all) or according to the
presence or absence of concomitant basal insulin therapy,
and whether DPP4i or gliclazide was being used as second-
line therapy after metformin. *p\ 0.05 for the indicated
comparisons. Bars indicate standard error
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insulin and oral therapy, which was greater
than the effect of gliclazide. The previous his-
tory of GLM use may be more reflective of
residual beta-cell function than disease dura-
tion. Although both DPP4i and gliclazide stim-
ulate endogenous insulin secretion, DPP4i exert
a more physiological meal-dependent action
and may be more able to improve beta and
alpha cell function [20].
These findings have clinical implications for
individualization of therapy based on patients’
history, indicating that DPP4i can be effective
also in a more advanced disease stage.
Although DPP4i are associated with a mark-
edly lower risk of hypoglycemia than SUs,
information on hypoglycemic events are not
yet available in the DARWIN-T2D database and
it is therefore impossible to weigh the benefits
of glucose control against the risk of hypo-
glycemia. Future real-world studies combining
clinical and administrative data on hospital
discharge codes will be useful to address this
issue.
In addition to the glucose-lowering potency
and the risk of hypoglycemia, there is great
focus on cardiovascular effects of drugs for the
treatment of T2D. The ongoing CAROLINA
trial, comparing linagliptin versus glimepiride,
will shed light on cardiovascular outcomes with
DPP4i versus SUs [21].
This study has limitations inherent to its
retrospective and non-randomized design.
Therefore, the level of evidence arising from
these data cannot be equated to that of RCTs.
The risk of confounding by indication and
reverse causality always limit interpretation of
the comparisons between therapeutic strategies
in observational studies. To address this issue,
we used PSM to obtain matched cohorts of
patients and simulate a quasi-experimental
design. With this tool, it is possible to emulate
the conditions of an RCT with respect to the
observed baseline characteristics. By PSM, we
have been able to obtain well-balanced groups,
except for a residual difference in the rate of
concomitant basal insulin use, at a magnitude
that may not be clinically relevant. Nonethe-
less, to account for this residual confounding,
the outcome analysis was adjusted for insulin
use or presented separately for insulin users and
non-users. Importantly, however, for as good as
a PSM can be, it does not guarantee equal dis-
tribution of unmeasured variables, making the
issue of residual confounders unresolved. Data
missingness was addressed with MI, but we
decided not to impute missing outcome vari-
ables. Since some patients had to be excluded
from the matched cohorts because of missing
values in secondary outcome variables, results
for FPG, body weight, and blood pressure have
to be considered with more caution than results
for HbA1c. Finally, since only a fraction of the
initial patient cohort could be matched, results
apply only to patients with the baseline clinical
characteristics obtained after PSM.
On the other hand, the study has remarkable
strengths. These include the large sample size,
the extensive patient characterization, the
multicenter nature with nationwide distribu-
tion, the rigorous consideration of biases, and
the automatic data extraction from the same
electronic chart, which guarantees repro-
ducibility, uniform data coding, and low
reporting bias.
CONCLUSION
Addition of a DPP4i to an ongoing glucose-
lowering regimen in Italian diabetes specialist
outpatient clinical practice improved glucose
control more than addition of gliclazide.
Although gliclazide was being used at submax-
imal doses and confounding cannot be defi-
nitely ruled out, these data confute the general
belief that initiation of SUs is highly effective in
reducing HbA1c and provide a rationale for
pragmatic trials comparing DPP4i and SU in a
routine clinical setting.
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